Mikael Persson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mikael Persson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Lars Gedda
Biomedical Radiation Sciences, Departments of
2 shared publications- Vladimir Tolmachev
UNIIM – Affiliated branch of the D. I. Mendeleyev Institute for Metrology
2 shared publications H. J. Jensen
1 shared publicationHans Lundqvist
Biomedical Radiation Sciences, Departments of
1 shared publication- Hans Lundqvist
Department of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden
1 shared publication Hans Nordgren
Molecular and Morphological Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
1 shared publication
Latest Publications
- 1 January 2007
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (1) , 326-331
[177Lu]Pertuzumab: Experimental Therapy of HER-2–Expressing Xenografts
Pertuzumab (Omnitarg) is a novel antibody against HER-2, domain II. HER-2 is a tyrosine kinase receptor that is overexpressed in several carcinomas, especially breast cancer. Pertuzumab, labeled with the low-energy β emitter 177Lu, might be a candidate for targeted radiotherapy of disseminated HER-2–positive micrometastases. The radiolabeled antibody [177Lu]pertuzumab showed favorable targeting properties in BALB/c (nu/nu) mice with HER-2–overexpressing xenografts. The absorbed dose in tumors was more than five times higher than the absorbed dose in blood and more than seven times the absorbed dose in any other normal organ. Experimental therapy showed that [177Lu]pertuzumab delayed tumor progression compared with controls (no treatment, P < 0.0001; nonlabeled pertuzumab antibody, P < 0.0001; and 177Lu-labeled irrelevant antibody, P < 0.01). No adverse side effects of the treatment could be detected. Thus, the experimental results support the planning of clinical studies applying [177Lu]pertuzumab for therapy. [Cancer Res 2007;67(1):326–31]
- 1 January 2007
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (1) , 326-331
[177Lu]Pertuzumab: Experimental Therapy of HER-2–Expressing Xenografts
Pertuzumab (Omnitarg) is a novel antibody against HER-2, domain II. HER-2 is a tyrosine kinase receptor that is overexpressed in several carcinomas, especially breast cancer. Pertuzumab, labeled with the low-energy β emitter 177Lu, might be a candidate for targeted radiotherapy of disseminated HER-2–positive micrometastases. The radiolabeled antibody [177Lu]pertuzumab showed favorable targeting properties in BALB/c (nu/nu) mice with HER-2–overexpressing xenografts. The absorbed dose in tumors was more than five times higher than the absorbed dose in blood and more than seven times the absorbed dose in any other normal organ. Experimental therapy showed that [177Lu]pertuzumab delayed tumor progression compared with controls (no treatment, P < 0.0001; nonlabeled pertuzumab antibody, P < 0.0001; and 177Lu-labeled irrelevant antibody, P < 0.01). No adverse side effects of the treatment could be detected. Thus, the experimental results support the planning of clinical studies applying [177Lu]pertuzumab for therapy. [Cancer Res 2007;67(1):326–31]
- 1 March 2006
- Published by Spandidos Publications in Oncology Reports
- Vol. 15 (3) , 673-680
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours
The anti-ErbB2 antibody trastuzumab is used for the treatment of patients with advanced breast cancer, resulting in a response rate of 40-60%. Coupling with a cytotoxic nuclide, e.g. alpha-emitting 211At, may further increase tumour response. The tumour-targeting properties of trastuzumab, astatinated using N-succinimidyl-para-(tri-n-methylstannyl)-benzoate, were evaluated and compared with those of radioiodinated trastuzumab in this study. We found that astatinated trastuzumab retains high specificity towards ErbB2. While the immunoreactive fraction of radioiodinated trastuzumab was higher than that of astatinated trastuzumab (76+/-9% versus 54+/-28%), both radioconjugates showed high affinity (KD 0.75+/-0.16 nM versus 1.8+/-0.3 nM). A growth inhibition study indicated a dose-dependent cell deactivation, in which approximately 74 cell-associated astatine decays per cell gave a survival fraction of 4.5+/-0.8x10(-4). Results of a comparative animal study on normal mice gave no indication that astatination would have any adverse effects on the biodistribution of the antibody. In conclusion, the results of the study suggest that astatinated trastuzumab is a promising candidate for treating ErbB2-expressing tumours.
- 1 March 2006
- Published by Spandidos Publications in Oncology Reports
- Vol. 15 (3) , 673-680
Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours
The anti-ErbB2 antibody trastuzumab is used for the treatment of patients with advanced breast cancer, resulting in a response rate of 40-60%. Coupling with a cytotoxic nuclide, e.g. alpha-emitting 211At, may further increase tumour response. The tumour-targeting properties of trastuzumab, astatinated using N-succinimidyl-para-(tri-n-methylstannyl)-benzoate, were evaluated and compared with those of radioiodinated trastuzumab in this study. We found that astatinated trastuzumab retains high specificity towards ErbB2. While the immunoreactive fraction of radioiodinated trastuzumab was higher than that of astatinated trastuzumab (76+/-9% versus 54+/-28%), both radioconjugates showed high affinity (KD 0.75+/-0.16 nM versus 1.8+/-0.3 nM). A growth inhibition study indicated a dose-dependent cell deactivation, in which approximately 74 cell-associated astatine decays per cell gave a survival fraction of 4.5+/-0.8x10(-4). Results of a comparative animal study on normal mice gave no indication that astatination would have any adverse effects on the biodistribution of the antibody. In conclusion, the results of the study suggest that astatinated trastuzumab is a promising candidate for treating ErbB2-expressing tumours.
- 29 September 2005
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 32 (12) , 1457-1462
[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells
The new antibody pertuzumab (Omnitarg) targets the dimerisation subdomain of HER-2. The purpose of this study was to analyse whether pertuzumab retains HER-2 targeting capacity after labelling with the therapeutically interesting beta emitter 177Lu and to make initial characterisations in vitro and in vivo.
- 29 September 2005
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 32 (12) , 1457-1462
[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells
The new antibody pertuzumab (Omnitarg) targets the dimerisation subdomain of HER-2. The purpose of this study was to analyse whether pertuzumab retains HER-2 targeting capacity after labelling with the therapeutically interesting beta emitter 177Lu and to make initial characterisations in vitro and in vivo.